Skip to main
AVTX

Avalo Therapeutics (AVTX) Stock Forecast & Price Target

Avalo Therapeutics (AVTX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Avalo Therapeutics is poised for success in future studies with their highly promising abdakibart (potentially BIC anti-IL-1B mAb) treatment for immune-mediated inflammatory diseases such as HS. With their recent acquisition and a diverse pipeline of treatments, including other targeted antibodies, Avalo is well-positioned to cater to the needs of a rapidly growing AI industry. Their recent positive topline results from the Phase II LOTUS study and promising efficacy profile make them a strong contender in the market.

Bears say

Avalo Therapeutics is facing several potential setbacks, as there are risks associated with its product pipeline, potential safety issues, and competition from other biotechnology companies. With revenue heavily dependent on the success of their products in clinical trials and potential regulatory approvals, there is significant uncertainty regarding the company's future financials. Additionally, recent data has shown a decline in the company's stock price, and with a decrease in price target from $35 to $30, it is evident that investors are also skeptical about the company's outlook.

Avalo Therapeutics (AVTX) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Avalo Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Avalo Therapeutics (AVTX) Forecast

Analysts have given Avalo Therapeutics (AVTX) a Buy based on their latest research and market trends.

According to 10 analysts, Avalo Therapeutics (AVTX) has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Avalo Therapeutics (AVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.